Omega-3 supplement for pulmonary arterial hypertension
Part of Lungs & breathing clinical trials.
This study tests whether a special omega-3 supplement (a type of fish oil) can reduce inflammation and improve blood vessel function in people with pulmonary arterial hypertension (PAH). If it helps, it might slow the disease and improve everyday symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a specific type of pulmonary arterial hypertension (PAH) — either without known cause, inherited, caused by weight-loss pills, or linked to connective tissue disease.
- Your PAH treatment has been unchanged for at least 3 months.
- You are not taking fish oil or omega-3 supplements daily, and you are not allergic to fish, shellfish, peanuts, soy, corn, or coconut oil.
- You are not on therapeutic-dose blood thinners, and you have not had a recent heart attack, stent, or blood clot in the lung in the past month (or 6 months for the clot).
- You are willing to give informed consent and, if you are a woman who could become pregnant, use effective contraception and have a negative pregnancy test.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special PET scan tracer (XBD173) to look at inflammation in the lungs of people with pulmonary arterial hypertension (PAH). It aims to understand the role of a protein called TSPO in PAH and may help guide future treatments.
This trial tests a new drug called IMC-003 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can help improve symptoms and exercise ability when added to your current PAH medications.
This trial tests a new combination of three medicines (including an experimental drug called sotatercept) for people recently diagnosed with PAH. The goal is to see if this early, powerful treatment works better than standard care in improving heart and lung function.
This trial tests whether an oral supplement made from special fats (called Specialized Pro-resolving Mediators) can help reduce blood vessel damage caused by inflammation in people with obesity and high blood pressure. If you have well-controlled high blood pressure and are obese, you may be able to join.
This study tests whether using a mobile health tool can help people with pulmonary arterial hypertension (PAH) manage their condition in daily life. It’s aimed at adults who are stable on their PAH medicines and can track activity using a wearable device.
This trial tests whether a combination of three medications works well and is safe for people newly diagnosed with pulmonary arterial hypertension (PAH) that is not low-risk. It aims to see if starting with triple therapy early can improve outcomes.
Hear when a new PAH trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.